Stock NGEN NERVGEN PHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

NervGen Pharma Corp. Stock

Equities

NGEN

CA64082X2032

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 03:59:58 2024-04-25 pm EDT 		5-day change 1st Jan Change
2.02 CAD -3.35% Intraday chart for NervGen Pharma Corp. +1.00% -25.19%
Apr. 17 NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update MT
Apr. 17 NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 146M 107M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.07%
More Fundamentals * Assessed data

Chart NervGen Pharma Corp.

Dynamic Chart

Latest news about NervGen Pharma Corp.

NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update MT
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NervGen Pharma Closes C$23 Million Bought Deal Financing MT
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units MT
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291 CI
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury CI
Nervgen Pharma Appoints John Ruffolo to Board of Directors CI
NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury CI
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Nervgen Pharma Corp. Receives Institutional Review Board Approval for Its Phase 1B/2A Proof-Of-Concept Clinical Trial Protocol of Its Proprietary Lead Compound, Nvg-291, in Individuals with Spinal Cord Injury CI
NervGen Pharma Corp. Receives $3.18 Million Grant from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury CI
NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nervgen Pharma Corp. Appoints Michael Kelly as CEO CI
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer MT
More news

Press releases NervGen Pharma Corp.

NervGen Engages Russo Partners LLC to Provide Public Relations Services NE
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates NE
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off AQ
NervGen Completes $23 Million Bought Deal Financing NE
Canadian Investment Regulatory Organization Trade Resumption - NGEN AQ
More press releases

Quotes and Performance

1 day-3.35%
1 week+1.00%
Current month-8.18%
1 month-7.76%
3 months-22.31%
6 months+1.51%
Current year-25.19%
More quotes

Highs and lows

1 week
2.00
Extreme 2
2.25
1 month
1.87
Extreme 1.87
2.34
Current year
1.87
Extreme 1.87
3.98
1 year
1.50
Extreme 1.5
3.98
3 years
1.26
Extreme 1.26
3.98
5 years
0.80
Extreme 0.8
3.98
10 years
0.80
Extreme 0.8
3.98
More quotes

Managers and Directors - NervGen Pharma Corp.

Managers TitleAgeSince
William Radvak FOU
 Founder 61 17-01-18
Michael Kelly CEO
 Chief Executive Officer 59 23-04-09
Bill Adams DFI
 Director of Finance/CFO 62 20-02-23
Members of the board TitleAgeSince
Randall Kaye BRD
 Director/Board Member 62 20-10-27
Brian Bayley BRD
 Director/Board Member 71 18-05-15
William Radvak FOU
 Founder 61 17-01-18
More insiders

Quotes

Date Price Change Volume
24-04-25 2.02 -3.35% 117,470
24-04-24 2.09 +1.46% 100,296
24-04-23 2.06 -3.29% 54,702
24-04-22 2.13 -4.48% 75,350
24-04-19 2.23 +11.50% 155,430

Delayed Quote Toronto S.E., April 25, 2024 at 03:59 pm EDT

More quotes

Company Profile

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.
Sector
Biotechnology & Medical Research
Calendar
2024-05-14 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.09 CAD
Average target price
5 CAD
Spread / Average Target
+139.23%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NERVGEN PHARMA CORP. Stock NervGen Pharma Corp.
-25.19% 107M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NGEN Stock